(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



) – Podlik Horrod in Kolonik Gere krist edio and i likki edist edid edeli lood istik birt eriken ikel keli idek

(43) International Publication Date 5 August 2004 (05.08.2004)

PCT

(10) International Publication Number WO 2004/064822 A1

- (51) International Patent Classification7: A61K 31/16, 31/445, 31/505, 35/36, 38/43, 47/10, 47/14, 31/40, A61P 35/00, 35/04
- (21) International Application Number:

PCT/AU2003/000719

- (22) International Filing Date: 10 June 2003 (10.06.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

7 June 2002 (07.06.2002) AU

- PS 2826
- (71) Applicant and
 (72) Inventor: SCOTT, Kieran, Francis [NZ/AU]; Unit 3/4
 Kent Street, Waverley, New South Wales 2024 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GRAHAM, Garry, George [AU/AU]; 1203/95 Brompton Road, Kensington, New South Wales 2033 (AU). DONG, Qihan [AU/AU]; 6/56 St Albans Street, Abbortsford, New South Wales 2046 (AU).

- (74) Agent: F B RICE & CO; 139 Rathdowne Street, Carlton, Victoria 3053 (AU).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF INHIBITING PROSTATE CANCER CELL PROLIFERATION

(57) Abstract: The present invention relates to a method of inhibiting or reducing the proliferation of prostate cancer cells, such as androgen independent prostate cancer (AIPC) cells, the method comprising administering to the cells a PLA2 inhibitor. In one embodiment the PLA2 inhibitor is a conformationally constrained molecule derived from a peptide consisting essentially of amino acid residues 70-74 of a human sPLA2-IIA protein, or the equivalent residues in other sPLA2 proteins.

04/064822 AI

10/517256

DT09 Rec'd PCT/PTO 0 7 DEC 2004

WO 2004/064822

ا الم الماري المارية المارية

PCT/AU2003/000719

1

Method of inhibiting prostate cancer cell proliferation

Field of the Invention

5 The present invention relates to a method of inhibiting proliferation of prostate cancer cells, such as in a method of treating prostate cancer. In particular, the invention relates to a method of inhibiting proliferation of androgen-independent prostate cancer cells.

10 Background of the invention

Prostate cancer occurs frequently in men, is currently the second most common cause of cancer-related death and incidence is growing. Prostatectomy is useful in the treatment of patients with cancer confined to the prostate. Androgen ablation therapy is used in cases where cancer cells still require androgens for growth but have spread beyond the prostate. To date, however, there is no effective treatment for metastatic Androgen-Independent Prostate Cancer (AIPC).

Our understanding of the aetiology of prostate cancer is limited and unlike certain other cancers, little progress has been made in elucidating its cause. Efforts have been made to identify genes responsible for familial prostate cancer. At least seven chromosomal loci have been reported, however the genes responsible for prostate cancer in all these loci have not yet been identified. Although an inherited genetic predisposition occurs in only 5-10% of cases, it is possible that identification of germline mutations may shed light on sporadic cases as both forms share the same histopathological features. The majority of researchers have focused on somatic defects in sporadic prostate cancer. Classical cytogenetic studies are difficult to apply to solid tumours and so far no consistent chromosomal changes have been observed. Although comparative genome hybridisation and loss of heterozygosity analysis have

shown both gain and loss of genomic DNA, the majority of genes involved are still unknown. Oncogenes and tumour suppressor genes known to be associated with other malignancies have a remarkably low frequency of mutation or deletion in prostate cancer. Using technologies that compare the steady-state mRNA levels between normal and cancerous prostate, a list of genes have been revealed to be either over or underexpressed in prostate cancer tissue or cell-lines. Although proteomics and tissue array approaches are now being used, relatively few genes have yet been verified to be differentially expressed in a reasonable number of specimens at the protein level. Direct evidence for the importance of these differentially expressed genes in prostate cancer initiation or progression is lacking. As a result, although progress is rapid, the application of this new knowledge in controlling mortality and morbidity from prostate cancer is slow at present.

15 Emerging evidence from epidemiological studies indicates a strong association between prostate cancer risk and total fat intake (Kolonel et al., 1999 J. Natl Cancer Inst. 91: 414), although the biochemical link between dietary lipids and genesis of prostate cancer remains unclear. Previous studies have demonstrated that both cyclooxygenase (COX) and lipoxygenase (LOX) 20 products of arachidonic acid metabolism, the prostaglandins (PG), and hydroxyeicosatetraenoic acids (HETEs) respectively, contribute to formation and/or progression of prostate cancer. They are implicated in promotion of tumour cell proliferation, motility, invasion and metastasis, and induction of angiogenesis both in vitro and in animal models. Interestingly, arachidonic acid 25 levels are lower in malignant than benign (BPH) prostate tissue while PG and HETE synthesis from labelled arachidonic acid is significantly increased. However, the activity of arachidonic acid mobilising enzymes phospholipase A2 (PLA₂) and fatty acyl-CoA lysophosphatidylcholine acyltransferase, are also increased, suggesting an increased flux of arachidonic acid through the COX 30 and LOX pathways.

PLA₂ constitutes a large and diverse family of enzymes that catalyse the hydrolysis of membrane phospholipids at the *sn*-2 position to release fatty acids and lysophospholipids. PLA₂ enzymes are classified according to their source and their cellular location (i.e secreted PLA₂ enzymes (sPLA₂s) or cytosolic PLA₂ enzymes (cPLA₂s)). A review of the classification and characterisation of the expanding superfamily of PLA₂ enzymes had been published by Six and Dennis (2000) *Biochim. Biophys. Acta* 1488:1-19.

sPLA₂-IIA is elevated in prostate cancer (Graff et al., 2001, Clin. Cancer Res. 7: 3857-3861; Jiang et al., 2002, Am. J. Pathol. 160: 667-671) and enhanced sPLA₂-IIA expression has been inversely related to 5-year patient survival (Graff et al., 2001). In addition, the chromosomal location of several sPLA₂ genes including sPLA₂-IIA (1p35-ter), overlaps with one prostate cancer susceptibility locus CAPB (Nwosu et al., 2001, Human Mol. Genet. 10: 2313-2318). To date, however, there has been no evidence to show that sPLA₂-IIA is involved in prostate tumorigenesis.

Summary of the invention

- We have now shown by immunohistochemistry in patients following androgen ablation therapy, that Type IIA secreted phospholipase A_2 (sPLA₂-IIA) is elevated in androgen-independent tumour cells relative to benign glands, while cytosolic phospholipase A_2 - α (cPLA₂- α) levels are unchanged.
- 25 We have also found that treatment of prostate cancer cells with sPLA₂-IIA potently increases proliferation of the cells, and that this proliferative effect is blocked by the addition of selective inhibitors of both sPLA₂-IIA and cPLA₂-α enzymes.

This provides evidence for the first time of the direct role of PLA₂ in the proliferation of prostate cancer cells and identifies this class of enzymes as an important therapeutic target for the treatment of prostate cancer.

5 Accordingly, in a first aspect the present invention provides a method of inhibiting or reducing the proliferation of prostate cancer cells, the method comprising administering to the cells a PLA₂ inhibitor.

In a second aspect the present invention provides a method for the treatment of prostate cancer, the method comprising administering to a subject in need thereof a PLA₂ inhibitor.

In a preferred embodiment of the first and second aspects, the prostate cancer cells are androgen independent prostate cancer (AIPC) cells.

15

In accordance with the first and second aspects of the present invention, the PLA_2 inhibitor may inhibit any PLA_2 enzyme. Preferably, the inhibitor inhibits an enzyme selected from group 1B, IIA, IID, IIE, IIF, III, IV, V, and X PLA_2 enzymes.

20

In one embodiment, the inhibitor is a cPLA₂-α inhibitor. For example, the inhibitor may be pyrrolidine-1, a substituted pyrimidine as described in WO 00/27824, a 9,10-dihydro-9,10-ethanoanthracene derivative as described in WO 99/15493, an azalomycin inhibitor as described in JP12119292, an arylsulfonamide as described in WO 98/25893, an indole-2-carboxylic acid derivative as described in WO 98/05637, an indole derivative as described in WO 98/08818, WO 99/43651, WO 99/43654 or WO 99/43672, a 3-sulfanyl-propane-1,2-diol derivative as described in JP12038380, a heterocyclic compound such as those described in WO 00/34254 or an oxazolidinedione or thiazolidinedione derivative as described in WO 97/05135 or WO 98/33797.

In another embodiment, the inhibitor is an sPLA₂-IIA inhibitor. For example, the inhibitor may be a benzoic acid as described in JP8325154, a 6-aza-spiro-[4,5]-decane derivative as described in JP9110835, amide derivatives of fatty acids such as those described in WO 00/00220 and WO 95/19959, (arylsulfonamidophnoxy) benzoic acids such as those described in WO 97/35567, fatty acid derivatives such as those described in WO 97/38966, tetronic acids such as those described in JP0045740, dinitrogen heterocyclic compounds such as those described in WO 98/05332, oxadiazine and thioxadiazine derivatives such as those described in WO 00/71118, sulfonylaminopyrazoles such as those described in WO 98/24437, (Indol-3-yl)acetamide inhibitors described in EP 839806, EP 950657, EP 952149 and WO 00/07590, (indol-3-yl) oxoacetamides such as those described in EP 675110, WO 98/37069, WO 99/59999, WO 99/51605, WO 00/07591, WO 00/37358 and WO 00/00201, or derivatives such as those described in WO 99/21545, WO 99/21546 and WO 99/21559.

In a particularly preferred embodiment the inhibitor is a conformationally constrained molecule derived from a peptide consisting essentially of amino acid residues 70 to 74 of a human sPLA₂-IIA protein, or the equivalent residues 20 in other sPLA₂-IIA proteins.

Preferably, the conformationally constrained molecule is a peptide, more preferably a cyclic peptide.

In a preferred embodiment, the conformationally constrained peptide is a cyclic peptide of the following formula:

A1-A2-A3-A4-A5
in which
A1 is F or Y or W or 2Nap
30 A2 is L or I
A3 is S or T

30

A4 is F or Y or W or 2Nap A5 is R or K.

In a further preferred embodiment of the present invention, the peptide is selected from the group consisting of cFLSYK, cFLSYR and c(2NapA)LS(2NapA)R.

When used herein the term "cFLSYK" means "cyclic FLSYK", "cFLSYR" means "cyclic FLSYR" and "c(2NapA)LS(2NapA)R" means "cyclic (2Nap)LS (2Nap)R".

The term "2NapA" is an abbreviation for 2-naphthylalanine.

In a further preferred embodiment, the peptide comprises D-amino acids and has a sequence which corresponds to the reverse sequence of a peptide according to the first aspect of the present invention.

In a preferred embodiment of the present invention, the method involves administration of a $SPLA_2$ -IIA inhibitor in conjunction with a $CPLA_2$ - α inhibitor.

In yet a further aspect the present invention provides the use of a PLA₂ inhibitor

20 in the manufacture of a medicament for the treatment of prostate cancer.

In yet a further aspect the present invention provides the use of a conformationally constrained molecule derived from a peptide consisting essentially of amino acid residues 70 to 74 of a human sPLA₂-IIA protein, or the equivalent residues in other sPLA₂-IIA proteins, in the manufacture of a medicament for the treatment of prostate cancer.

In yet another aspect the present invention provides a method for detecting prostate cancer or a metastasis thereof in a subject, said method comprising:

determining the level of $\ensuremath{\text{PLA}}_2$ mRNA expressed in a test sample from said subject; and

15

comparing the level of PLA₂ mRNA determined at (i) to the level of PLA₂.mRNA expressed in a comparable sample from a healthy or normal individual,

wherein a level of PLA₂ mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of a cancer cell in said subject.

In yet another aspect the present invention provides a method for detecting prostate cancer or a metastases thereof in a subject, said method comprising:

determining the level of a PLA₂ polypeptide in a test sample from said subject; and

comparing the level of PLA₂ polypeptide determined at (i) to the level of said PLA₂ polypeptide in a comparable sample from a healthy or normal individual,

wherein a level of said PLA₂ polypeptide at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of a cancer cell in said subject.

In yet another aspect the present invention provides a method of assessing the predisposition of a subject to prostate cancer, the method comprising the step of determining the presence of a polymorphism or an epigenetic change in a PLA₂ gene of the subject.

PCT/AU2003/000719

Brief description of the Figures

Figure 1. Effect of androgen ablation therapy on sPLA₂-IIA protein expression. Prostate tissue from patients following radical prostatectomy either with (N = 25) or without (N=50) prior androgen ablation therapy were examined for sPLA₂-IIA protein expression by immunohistochemistry as described in Materials and Methods. A. Adjacent sections from a patient without androgenablation therapy showing normal glands. B. Adjacent sections from a patient following androgen ablation therapy showing both normal and neoplastic tissue.

10 Left panel stained with haematoxilin and eosin, right panel stained with antisPLA₂-IIA antibody. Magnification, x 40. C. sPLA₂-IIA expression in normal (open boxes) or neoplastic (closed boxes) tissue from patients with (+) or without (-) androgen ablation therapy was graded on a 3-point score, (1; 0 - 33% tissue positive, 2; 33 - 66% tissue positive and 3; >66% tissue positive).

15 *; P < 0.05 vs no androgen ablation therapy treated benign glands by Chi-Square analysis.

Figure 2. Effect of exogenous addition of sPLA₂-IIA on prostate cell growth. LNCaP cells were grown in RPMI with 5% FCS and treated for 72 hours in media containing (A) increasing concentrations of sPLA₂-IIA alone (closed bars) or increasing concentrations of the activity-dead sPLA₂-IIA mutant H₄₈Q. (B) a fixed concentration of sPLA₂-IIA and increasing concentrations of the sPLA₂-IIA inhibitor cFLSYR. Cell number relative to untreated control cells was determined by the MTS assay as described in Materials and Methods. Data are Mean ± SD of quadruplicate determinations normalised to 100% for untreated cells. OD₄₉₅ of unstimulated cells was 0.29 ±0.06 for sPLA₂-IIA and 0.24 ± 0.03 for the sPLA₂-IIA mutant experiments in panel A and 0.24 ± 0.03 for panel B. * p<0.05 vs untreated control by one-way ANOVA. Data are representative of three separate experiments. (C). LNCaP cells were grown as above and stimulated for 72 hours with sPLA₂-IIA (1 nM) in the absence (dotted lines) and presence (solid lines) of the sPLA₂-IIA inhibitor cFLSYR (100 nM). Cells

(1x10⁶) were assayed by flow cytometry following treatment with propidium iodide as described in Materials and Methods. Statistical analysis was performed on 10,000 events per sample. Data are representative of three separate experiments.

Figure 3. Effect of inhibition of cPLA₂- α on sPLA₂-IIA-dependent proliferation. LNCaP cells were grown in RPMI containing 5% FCS and stimulated for 72 hours with sPLA2-IIA (1 nM) in the presence (hatched bars) and absence (closed bar) of increasing concentrations of the cPLA2-α-selective inhibitor 10 pyrrolidine-1. Cell number was determined by the MTS assay as described in Materials and Methods. Data are mean ± SD of quadruplicate determinations expressed as percentages relative to untreated control cells (100%) (open bar). OD_{495} of untreated cells was 0.33 \pm 0.03. In the presence of pyrrolidine-1 (5 uM) alone, OD₄₉₅ was 0.38 ± 0.04 * p<0.05 vs untreated control by one-way

15 ANOVA.

Figure 4. Effect of sPLA2-IIA inhibition on unstimulated prostate cancer cells. (A) The endogenous expression of sPLA2-IIA mRNA was evaluated by RT-PCR in three unstimulated prostate cancer cell lines (LNCaP, DU145 and PC-20 3) grown in RPMI containing 5% FCS. HPRT was used to as a positive control for RNA integrity and loading. (B) Cells were grown in RPMI with 5% FCS were then treated for 72 hours in the presence and absence of the sPLA2-IIA inhibitor c(2Nap)LS(2Nap)R and cell number determined by MTS assay as described in Materials and Methods. Data are mean ± SD of guadruplicate 25 determinations expressed as percentages relative to untreated control cells (100%). LNCaP, closed bars, OD₄₉₅ untreated cells 0.50 ± 0.03; DU145, open bars, OD₄₉₅ untreated cells 0.73 ± 0.05; PC-3, hatched bars, OD₄₉₅ untreated cells, 0.66 ±0.01. * p<0.05 vs untreated control by one-way ANOVA.

WO 2004/064822 PCT/AU2003/000719

10

Detailed description of the invention

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g. in cell culture, molecular genetics, nucleic acid chemistry, hybridization techniques and biochemistry). Standard techniques are used for molecular, genetic and biochemical methods (see generally, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. and Ausubel et al., Short Protocols in Molecular Biology (1999) 4th Ed, John Wiley & Sons, Inc. - and the full version entitled Current Protocols in Molecular Biology, which are incorporated herein by reference) and chemical methods.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

20 PLA₂ Enzymes

The methods of the present invention encompass targeting any PLA₂ enzyme. A review of the classification and characterisation of the expanding superfamily of PLA₂ enzymes had been published by Six and Dennis (2000) *Biochim.*25 *Biophys. Acta* 1488:1-19, and the present methods contemplate targeting all of these enzymes.

In preferred embodiments of the present invention, the PLA_2 enzyme is $sPLA_2$ -IIA or $cPLA_2$ - α . Preferably, the PLA_2 enzyme is a human enzyme.

The nucleic acid and protein sequences for human $sPLA_2$ -IIA are shown in SEQ ID NOs:1 and 3 respectively. The nucleic acid and protein sequences for human $cPLA_2$ - α are shown in SEQ ID NOs:2 and 4 respectively.

5 PLA₂ Inhibitors

Protein or Peptide inhibitors

In one embodiment, peptidyl PLA₂ inhibitors are chemically or recombinantly synthesized as oligopeptides (approximately 10-25 amino acids in length) derived from the a PLA₂ sequence (for example, SEQ ID NO:3 or 4). Alternatively, PLA₂ fragments are produced by digestion of native or recombinantly produced PLA₂ by, for example, using a protease, e.g., trypsin, thermolysin, chymotrypsin, or pepsin. Computer analysis (using commercially available software, e.g. MacVector, Omega, PCGene, Molecular Simulation, Inc.) is used to identify proteolytic cleavage sites. The proteolytic or synthetic fragments can comprise as many amino acid residues as are necessary to partially or completely inhibit PLA₂ function. Preferred fragments will comprise at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids in length.

Protein or peptide inhibitors may also be dominant-negative mutants of PLA₂. The term "dominant-negative mutant" refers to a PLA₂ polypeptide that has been mutated from its natural state and that interacts with a protein that PLA₂ normally interacts with thereby preventing endogenous native PLA₂ from forming the interaction.

Anti-PLA₂ Antibodies

30 The term "antibody" as used in this invention includes intact molecules as well as fragments thereof, such as Fab, F(ab')2, and Fv which are capable of

WO 2004/064822 PCT/AU2003/000719

12

binding an epitopic determinant of PLA₂. These antibody fragments retain some ability to selectively bind with its antigen and are defined as follows:

- (1) Fab, the fragment which contains a monovalent antigen-binding fragment
 of an antibody molecule can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain;
- (2) Fab', the fragment of an antibody molecule can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule;
- (3) (Fab')2, the fragment of the antibody that can be obtained by treating
 whole antibody with the enzyme pepsin without subsequent reduction; F(ab)2 is a dimer of two Fab' fragments held together by two disulfide bonds;
- (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed
 20 as two chains; and
- (5) Single chain antibody ("SCA"), defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

Methods of making these fragments are known in the art. (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1988), incorporated herein by reference).

Antibodies of the present invention can be prepared using intact PLA₂ or fragments thereof as the immunizing antigen. A peptide used to immunize an animal can be derived from translated cDNA or chemical synthesis and is purified and conjugated to a carrier protein, if desired. Such commonly used carriers which are chemically coupled to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid. The coupled peptide may then be used to immunize the animal (e.g., a mouse or a rabbit).

If desired, polyclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the peptide to which the antibodies were raised is bound. Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (See for example, Coligan, et al., Unit 9, Current Protocols in Immunology, Wiley Interscience, 1991, incorporated by reference).

Monoclonal antibodies may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture, such as, for example, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler et al. Nature 256, 495-497, 1975; Kozbor et al., J. Immunol. Methods 81, 31-42, 1985; Cote et al., Proc. Natl. Acad. Sci. USA 80, 2026-2030, 1983; Cole et al., Mol. Cell Biol. 62, 109-120, 1984).

25

Methods known in the art allow antibodies exhibiting binding for PLA₂ to be identified and isolated from antibody expression libraries. For example, a method for the identification and isolation of an antibody binding domain which exhibits binding to PLA₂ is the bacterio-phage a vector system. This vector system has been used to express a combinatorial library of Fab fragments from the mouse antibody repertoire in Escherichia coli (Huse, et al., Science,

246:1275-1281, 1989) and from the human antibody repertoire (Mullinax, et al., Proc. Nat. Acad. Sci., 87:8095-8099, 1990). This methodology can also be applied to hybridoma cell lines expressing monoclonal antibodies with binding for a preselected ligand. Hybridomas which secrete a desired monoclonal antibody can be produced in various ways using techniques well understood by those having ordinary skill in the art and will not be repeated here. Details of these techniques are described in such references as Monoclonal Antibodies-Hybridomas: A New Dimension in Biological Analysis, Edited by Roger H. Kennett, et al., Plenum Press, 1980; and U.S. 4,172,124, incorporated by reference.

In addition, methods of producing chimeric antibody molecules with various combinations of "humanized" antibodies are known in the art and include combining murine variable regions with human constant regions (Cabily, et al. Proc. Natl. Acad. Sci. USA, 81:3273, 1984), or by grafting the murine-antibody complementarity determining regions (CDRs) onto the human framework (Riechmann, et al., Nature 332:323, 1988).

Antisense compounds

20

The term "antisense compounds" encompasses DNA or RNA molecules that are complementary to at least a portion of a PLA₂ mRNA molecule (Izant and Weintraub, Cell 36:1007-15, 1984; Izant and Weintraub, Science 229(4711):345-52, 1985) and capable of interfering with a post-transcriptional event such as mRNA translation. Antisense oligomers complementary to at least about 15 contiguous nucleotides of PLA₂-encoding mRNA are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target PLA₂-producing cell. The use of antisense methods is well known in the art (Marcus-Sakura, Anal. Biochem. 172: 289, 1988). Preferred antisense nucleic acid will comprise a nucleotide

sequence that is complementary to at least 15 contiguous nucleotides of a sequence encoding the amino acid sequence set forth in SEQ ID NO:3 or 4.

Catalytic nucleic acids

5

The term catalytic nucleic acid refers to a DNA molecule or DNA-containing molecule (also known in the art as a "DNAzyme") or an RNA or RNA-containing molecule (also known as a "ribozyme") which specifically recognizes a distinct substrate and catalyzes the chemical modification of this substrate. The nucleic acid bases in the catalytic nucleic acid can be bases A, C, G, T and U, as well as derivatives thereof. Derivatives of these bases are well known in the art.

Typically, the catalytic nucleic acid contains an antisense sequence for specific recognition of a target nucleic acid, and a nucleic acid cleaving enzymatic activity (also referred to herein as the "catalytic domain"). To achieve specificity, preferred ribozymes and DNAzymes will comprise a nucleotide sequence that is complementary to at least about 12-15 contiguous nucleotides of a sequence encoding the amino acid sequence set forth in SEQ ID NO:3 or

20 4.

The types of ribozymes that are particularly useful in this invention are the hammerhead ribozyme (Haseloff and Gerlach 1988, Perriman et al., 1992) and the hairpin ribozyme (Shippy et al., 1999).

25

The ribozymes of this invention and DNA encoding the ribozymes can be chemically synthesized using methods well known in the art. The ribozymes can also be prepared from a DNA molecule (that upon transcription, yields an RNA molecule) operably linked to an RNA polymerase promoter, e.g., the promoter for T7 RNA polymerase or SP6 RNA polymerase. Accordingly, also provided by this invention is a nucleic acid molecule, i.e., DNA or cDNA, coding

for the ribozymes of this invention. When the vector also contains an RNA polymerase promoter operably linked to the DNA molecule, the ribozyme can be produced in vitro upon incubation with RNA polymerase and nucleotides. In a separate embodiment, the DNA can be inserted into an expression cassette or transcription cassette. After synthesis, the RNA molecule can be modified by ligation to a DNA molecule having the ability to stabilize the ribozyme and make it resistant to RNase. Alternatively, the ribozyme can be modified to the phosphothio analog for use in liposome delivery systems. This modification also renders the ribozyme resistant to endonuclease activity.

10

RNA inhibitors

dsRNA is particularly useful for specifically inhibiting the production of a particular protein. Although not wishing to be limited by theory, Dougherty and 15 Parks (1995) have provided a model for the mechanism by which dsRNA can be used to reduce protein production. This model has recently been modified and expanded by Waterhouse et al. (1998). This technology relies on the presence of dsRNA molecules that contain a sequence that is essentially identical to the mRNA of the gene of interest, in this case an mRNA encoding a 20 PLA₂ protein. Conveniently, the dsRNA can be produced in a single open reading frame in a recombinant vector or host cell, where the sense and antisense sequences are flanked by an unrelated sequence which enables the sense and anti-sense sequences to hybridize to form the dsRNA molecule with the unrelated sequence forming a loop structure. The design and production of 25 suitable dsRNA molecules targeted agasint PLA2 is well within the capacity of a person skilled in the art, particularly considering Dougherty and Parks (1995), Waterhouse et al. (1998), WO 99/32619, WO 99/53050, WO 99/49029, and WO 01/34815.

30 As used herein, the terms "small interfering RNA", and "RNAi" refer to homologous double stranded RNA (dsRNA) that specifically targets a gene

product, thereby resulting in a null or hypomorphic phenotype. Specifically, the dsRNA comprises two short nucleotide sequences derived from the target RNA encoding PLA₂ and having self-complementarity such that they can anneal, and interfere with expression of a target gene, presumably at the post-transcriptional level. RNAi molecules are described by Fire et al., Nature 391, 806-811, 1998, and reviewed by Sharp, Genes & Development, 13, 139-141, 1999).

Small molecule inhibitors

10

Small molecule inhibitors that regulate PLA₂ are described in Lehr (2001) Expert Opin. Ther. Patents (2001) 11 (7):1123-1136, and Hansford *et al* (2003) Chem. Biochem. <u>4</u>:181-185.

15 Peptides and peptide analogues

In preferred embodiments, the methods of the present invention involve the administration of conformationally constrained molecules derived from a peptide consisting essentially of amino acid residues 70 to 74 of a human splay-IIA protein, or the equivalent residues in other splay-IIA proteins.

In general, reference to amino acid residues 70 to 74 of the human sPLA₂-IIA protein is taken to include reference to the equivalent residues in other sPLA₂-IIA proteins, such as orthologues of human sPLA₂-IIA.

25

The term "conformationally constrained molecules" means conformationally constrained peptides and conformationally constrained peptide analogues and derivatives.

30 Thus the conformationally constrained molecules according to the present invention include conformationally constrained peptides consisting essentially

of residues 70 to 74 of the human sPLA₂-IIA protein, and analogues and derivatives thereof.

The term "analogues" refers to molecules having a chemically analogous structure to the naturally occurring alpha-amino acids present as residues 70 to 74 of the human sPLA₂-IIA protein. Examples include molecules containing *gem*-diaminoalkyl groups or alklylmalonyl groups.

The term "derivatives" includes alpha amino acids wherein one or more side groups found in the naturally occurring alpha-amino acids present as residues 70 to 74 of human sPLA₂-IIA protein have been modified. Thus, for example the naturally-occurring amino acids present in residues 70 to 74 of the human sPLA₂-IIA protein may be replaced with a variety of uncoded or modified amino acids such as the corresponding D-amino acid or N-methyl amino acid. Other modifications include substitution of hydroxyl, thiol, amino and carboxyl functional groups with chemically similar groups.

The present invention encompasses the use of conformationally constrained peptidomimetics of the biologically active human sPLA₂-IIA peptide (amino acid residues 70 to), i.e. analogues and derivatives which mimic the activity of said peptide and are therefore capable of inhibiting the sPLA₂-IIA dependent proliferation of prostate cancer cells. These peptidomimetics are preferably substantially similar in both three-dimensional shape and biological activity to the specific sPLA₂-IIA peptides described herein. Substantial similarity means that the geometric relationship of groups in the peptide that react with the sPLA₂-IIA enzyme is preserved and at the same time, that the peptidomimetic will inhibit the sPLA₂-IIA dependent proliferation of prostate cancer cells.

A peptidomimetic is a molecule that mimics the biological activity of a peptide 30 but is no longer peptidic in chemical nature. By strict definition, a peptidomimetic is a molecule that no longer contains any peptide bonds (that WO 2004/064822 PCT/AU2003/000719

19

is, amide bonds between amino acids). However, the term peptide mimetic is sometimes used to describe molecules that are no longer completely peptidic in nature, such as pseudo-peptides, semi-peptides and peptoids. Whether completely or partially non-peptide, peptidomimetics for use in the methods of the invention provide a spatial arrangement of reactive chemical moieties that closely resembles the three-dimensional arrangement of active groups in the peptide on which the peptidomimetic is based. As a result of this similar active-site geometry, the peptidomimetic has effects on biological systems which are similar to the biological activity of the peptide.

10

There are clear advantages for using a mimetic of a given peptide rather than the peptide itself, because peptides commonly exhibit two undesirable properties: (1) poor bioavailability; and (2) short duration of action. Peptide mimetics offer an obvious route around these two major obstacles, since the molecules concerned are small enough to be both orally active and have a long duration of action. There are also considerable cost savings and improved patient compliance associated with peptide mimetics, since they can be administered orally compared with parenteral administration for peptides. Furthermore, peptide mimetics are much cheaper to produce than peptides.

20

Suitable peptidomimetics based on residues 70 to 74 of human sPLA₂-IIA peptides and having similar biological activities, and therefore similar therapeutic utilities, can be developed using readily available techniques. Thus, for example, peptide bonds can be replaced by non-peptide bonds that allow the peptidomimetic to adopt a similar structure, and therefore biological activity, to the original peptide. Further modifications can also be made by replacing chemical groups of the amino acids with other chemical groups of similar structure. The development of peptidomimetics derived from sPLA₂-IIA peptides based on residues 70 to 74 of human sPLA₂-IIA can be aided by determining the tertiary structure of the original peptide by NMR spectroscopy, crystallography and/or computer-aided molecular modelling. These techniques

aid in the development of analogues/derivatives of higher potency and/or greater bioavailability and/or greater stability than the original peptide (Dean, 1994, BioEssays, 16: 683-687; Cohen and Shatzmiller, 1993, J. Mol. Graph., 11: 166-173; Wiley and Rich, 1993, Med. Res. Rev., 13: 327-384; Moore, 1994, Trends Pharmacol. Sci., 15: 124-129; Hruby, 1993, Biopolymers, 33: 1073-1082; Bugg et al., 1993, Sci. Am., 269: 92-98.

Information on the structure of an sPLA₂-IIA peptide consisting essentially of residues 70 to 74 of human sPLA₂-IIA can be used to search three-dimensional databases to identify molecules having a similar structure, using programs such as MACCS-3D and ISIS/3D (Molecular Design Ltd., San Leandro, CA), ChemDBS-3D (Chemical Design Ltd., Oxford, U.K.), and Sybyl/3DB Unity (Tripos Associates, St. Louis, MO).

- Databases of chemical structures are available from a number of sources including Cambridge Crystallographic Data Centre (Cambridge, U.K.), Chemical Abstracts Service (Columbus, OH), and ACD-3D (Molecular Design Ltd).
- 20 De novo design programs include Ludi (Accelrys), Leapfrog (Tripos Associates) and Aladdin (Daylight Chemical Information Systems, Irvine, CA).

Those skilled in the art will recognize that the design of a mimetic may require slight structural alteration or adjustment of a chemical structure designed or identified using these databases.

Peptide derivatives and peptidomimetic compounds based on amino acid residues 70 to 74 of human sPLA₂-IIA can be tested to determine whether they are capable of inhibiting sPLA₂-IIA dependent proliferation of prostate cancer cells using the assay described herein. Preferred peptide derivatives and peptidomimetics have at least 90%, preferably at least the same anti-

proliferative activity toward prostate cancer cells as cFLSYR. It is also preferred that peptide derivatives and peptidomimetics specifically inhibit sPLA₂-IIA.

5 The molecules, such as peptides, used in the methods of the present invention are conformationally constrained. Conformational constraint refers to the stability and preferred conformation of the three-dimensional shape assumed by a peptide. Conformational constraints include local constraints, involving restricting the conformational mobility of a single residue in a peptide; regional constraints, involving restricting the conformational mobility of a group of residues, which residues may form some secondary structural unit; and global constraints, involving the entire peptide structure.

The active conformation of a peptide may be stabilized by a covalent modification, such as cyclization or by incorporation of gamma-lactam or other types of bridges. For example, side chains can be cyclized to the backbone so as create a L-gamma-lactam moiety on each side of the interaction site. See, generally, Hruby et al., 1992, "Applications of Synthetic Peptides," in Synthetic Peptides: A User's Guide: 259-345 (W. H. Freeman & Co.). Cyclization also can be achieved, for example, by formation of cystine bridges, coupling of amino and carboxy terminal groups of respective terminal amino acids, or coupling of the amino group of a Lys residue or a related homolog with a carboxy group of Asp, Glu or a related homolog. Coupling of the alpha-amino group of a polypeptide with the epsilon-amino group of a lysine residue, using iodoacetic anhydride, can be also undertaken. See, for example, Wood and Wetzel, 1992, Int'l J. Peptide Protein Res. 39: 533-39.

Another approach described in US 5,891,418 is to include a metal-ion complexing backbone in the peptide structure. Typically, the preferred metal-30 peptide backbone is based on the requisite number of particular coordinating groups required by the coordination sphere of a given complexing metal ion. In

general, most of the metal ions that may prove useful have a coordination number of four to six. The nature of the coordinating groups in the peptide chain includes nitrogen atoms with amine, amide, imidazole, or guanidino functionalities; sulfur atoms of thiols or disulfides; and oxygen atoms of hydroxy, phenolic, carbonyl, or carboxyl functionalities. In addition, the peptide chain or individual amino acids can be chemically altered to include a coordinating group, such as for example oxime, hydrazino, sulfhydryl, phosphate, cyano, pyridino, piperidino, or morpholino.

- A further approach approach is to use bifunctional crosslinkers, such as N-succinimidyl 3-(2 pyridyldithio) propionate, succinimidyl 6-[3-(2 pyridyldithio) propionamido] hexanoate; and sulfosuccinimidyl 6-[3-(2 pyridyldithio) propionamido]hexanoate (see US Patent 5,580,853).
- 15 Techniques for chemically synthesising the peptides and derivatives described above are described in the above references and also reviewed by Borgia and Fields, 2000, *TibTech* 18: 243-251 and described in detail in the references contained therein.

20 <u>Diagnostic methods</u>

The present invention also encompasses nucleic acid-based methods and protein-based methods for diagnosing prostate cancer in humans and other mammals.

25

As used herein, the term "diagnosis", and variants thereof, such as, but not limited to "diagnose", "diagnosed" or "diagnosing" shall not be limited to a primary diagnosis of a clinical state, however should be taken to include any primary diagnosis or prognosis of a clinical state. For example, the "diagnostic assay" formats described herein are equally relevant to assessing the remission of a patient, or monitoring disease recurrence, or tumor recurrence,

such as following surgery or chemotherapy, or determining the appearance of metastases of a primary tumor. All such uses of the assays described herein are encompassed by the present invention.

5 Accordingly, the level of PLA₂ expression, at either the RNA level or the protein level, can be used to diagnose prostate cancer, or as a prognostic to monitor the progress of prostate cancer.

Preferred nucleic acid-based diagnostic assays rely upon the detection or relative quantification of RNA levels in samples using probes of at least about 20 nucleotides in length that hybridize specifically to RNA encoding PLA₂, or alternatively, amplify cDNA from RNA encoding PLA₂. Conveniently, any hybridization assay format can be used to detect PLA₂-encoding RNA in samples, such as, for example, high-throughput screening using microarray technology, or conventional northern hybridization or reverse transcription polymerase chain reaction (i.e. RT-PCR). In situ localization can also be employed using histology specimens.

Suitable diagnostic immunoassays utilize antibodies, including monoclonal and polyclonal antibodies, or a Fab fragment, F(ab')2 fragment, or scFv fragment, that binds to a unique peptide region comprising at least about 5-10 contiguous amino acid residues of PLA₂.

The present invention further encompasses any synthetic or recombinant peptides, or antibodies suitable for use in the assays described herein.

In preferred embodiments of these diagnostic methods the PLA2 is sPLA2-IIA or cPLA2- α .

30 In another aspect, the invention relates to methods of diagnosing for predisposition to prostate cancer.

WO 2004/064822 PCT/AU2003/000719

24

Accordingly, in one aspect the present invention provides a method of assessing the predisposition of a subject to prostate cancer, the method comprising the step of determining the presence of a polymorphism or an epigenetic change in a PLA₂ gene of the subject.

5

In one embodiment, the polymorphism is a PLA₂ polymorphism already identified in a public or private database such as the NCBI database or the Celera database.

The present invention encompasses nucleic-acid based methods and proteinbased methods for diagnosing susceptibility to prostate cancer.

The polymorphism in the PLA₂ gene may be a point mutation (i.e. a single nucleotide polymorphism (SNP)), deletion and/or insertion. Such a polymorphism may be detected by isolating and sequencing DNA fragments from the PLA₂ gene or otherwise by isolating mRNA from the individual and synthesising DNA therefrom (e.g. by RT-PCR) for sequencing. Polymorphisms may also be detected by hybridisation using discriminating oligonucleotide probes or by amplification procedures using discriminating oligonucleotide primers. Suitable methods may involve Southern analysis of genomic DNA; direct mutation analysis by restriction enzyme digestion; Northern analysis of RNA; denaturing high pressure liquid chromatography (DHPLC); gene isolation and sequencing; hybridization of an allele-specific oligonucleotide with amplified gene products; exon trapping, single base extension (SBE); or analysis of a PLA₂ protein.

In one embodiment the epigenetic change is aberrant methylation in a PLA_2 gene of the subject or insertion of an endogenous retroviral promoter or transposable element promoter close to a PLA_2 gene of the subject.

Methods of screening for therapeutic agents

Also encompassed by the present invention are methods of identifying therapeutic agents useful for the treatment of prostate cancer.

Accordingly, in a first aspect the present invention provides a method of screening for a compound that reduces or inhibits the proliferation of prostate cells, the method comprising determining the activity of PLA₂ in the presence and absence of a candidate compound, wherein reduced PLA₂ activity in the presence of the compound indicates that the compound reduces or inhibits the proliferation of prostate cells.

In another aspect, the present invention provides a method of screening for a compound that reduces or inhibits the proliferation of prostate cells, the method comprising determining the expression levels of PLA₂ in the presence and absence of a candidate compound, wherein reduced PLA₂ expression in the presence of the compound indicates that the compound reduces or inhibits the proliferation of prostate cells.

20 In a further embodiment of this aspect, the method involves exposing a translation system capable of expressing PLA₂ to a candidate compound and comparing the levels of expression of PLA₂ in the presence of the compound to the levels achieved under similar conditions but in the absence of the compound. The translation system may be a cell-free translation system.
25 Alternatively, the translation system may comprise eukaryotic or prokaryotic cells.

In a further aspect the present invention provides a method of screening for a compound that reduces or inhibits the proliferation of prostate cells, the method comprising determining the ability of a candidate compound to modulate the binding of PLA₂ to a PLA₂ substrate, wherein an altered level of binding of PLA₂ to the substrate in the presence of the compound indicates that the compound reduces or inhibits the proliferation of prostate cells.

In preferred embodiments of these screening methods the PLA₂ is sPLA₂-IIA or cPLA₂- α .

WO 2004/064822 PCT/AU2003/000719

26

Therapeutic methods

We have shown that administration of exogenous sPLA₂-IIA to prostate cells stimulates cell proliferation. We have also shown that administration of PLA₂ inhibitors inhibits sPLA₂-IIA mediated cell proliferation. Consequently, PLA₂ inhibitors can be used to inhibit or reduce prostate cell proliferation in cells, particularly in cells with elevated sPLA-IIA activity such as prostate cancer cells.

10

The PLA₂ inhibitors can be used therapeutically for prostate cancers, particularly AIPCs. The term "therapeutically" or as used herein denotes both prophylactic as well as therapeutic administration. Thus, PLA₂ inhibitors can be administered to high-risk patients in order to lessen the likelihood and/or severity of prostate cancer or administered to patients already evidencing prostate cancer.

The peptides, analogues and small molecule inhibitors described above may preferably be combined with various components to produce compositions.

Preferably the compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use). Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline, water, dry powders and micelles. The composition may be administered by any means known in the art. Modes of delivery include, but are not limited to, direct injection, topical delivery (e.g. by atomised nasal delivery or nasal drops) or oral delivery. Accordingly, the composition may be formulated, *inter alia*, for topical, parenteral, intramuscular, intravenous, subcutaneous, intraocular, oral or transdermal administration.

WO 2004/064822 PCT/AU2003/000719

27

Typically, each peptide or analogue or derivative thereof may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.

The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

The present invention will now be described further with reference to the following examples which are intended to be illustrative only and non-limiting.

EXAMPLES

Materials and Methods

15

Cell Lines and Culture. The LNCaP, DU145 and PC3 cell lines were purchased from American Type Culture Collection (Rockville, MD). All cell cultures were maintained in RPMI 1640 supplemented with 5% FBS for LNCaP and 10% FBS for DU145 and PC3 at 37°C in a humidified environment of 5% CO₂. For experiments with addition of androgens, cells were cultured in RPMI 1640 without phenol red and supplemented with same concentration of charcoal stripped FBS. For experiments described in this article, we used cells between passage 30 and 45 for LNCaP, 65 and 80 for DU145 and 25 and 40 for PC3.

25 Reagents. sPLA₂-IIA was purified by immunoaffinity chromatography from conditioned media derived from Chinese hamster ovary cell line (5A2) expressing human sPLA₂-IIA as described (Bidgood, M.J. et al. J. Immunol. (2000) 165:2790-2797). A cDNA encoding the activity-dead mutant sPLA₂-IIA H₄₈Q was constructed by oligonucleotide-mediated site-directed mutagenesis using standard molecular techniques. This cDNA was expressed in Chinese hamster ovary cells under the control of the human metallothionein promoter.

H₄₈Q was purified from conditioned media derived from this cell line by immunoaffinity chromatography. Purity was verified by the presence of a single band on a silver-stained SDS gel and by amino terminal peptide sequence analysis. Enzyme activity was undetectable in the purified protein as determined by the radiolabelled *Eschericia coli* assay (Church, W.B. et al. (2001), J. Biol. Chem. 276:33156-33614). Both mutant protein and sPLA₂-IIA were quantified by ELISA (Smith, G.M. et al., Br. J. Rheumatol. (1992) 31: 175). sPLA₂-IIA inhibitors (Church, W.B. et al) were synthesised using Fmoc (N-(9-fluoroenyl)methoxycarbonyl) solid phase chemistry without removal of side-chain protection groups prior to cleavage from the resin. Peptides were cyclised using standard peptide synthesis activation and coupling chemistry prior to deprotection (Auspep, Melbourne). The cPLA₂ inhibitor pyrrolidone-1 was a kind gift from Dr Michael Gelb.

- 15 Antibodies used in these experiments included polyclonal anti-sPLA₂-IIa (160502, Cayman Chemicals, monoclonal anti-sPLA₂-IIA antibody 4A1 raised by ourselves (Smith, G.M. *et al.*), and anti-cPLA₂ polyclonal antibody (SC-438, Santa Cruz).
- 20 Cell growth assay. Cells were plated at 1 x 10⁴ per well in 96-well plates with 0.1 ml of FBS-supplemented RPMI. After reaching 70-80% confluence (about 48 hours), the medium was changed to that containing various treatments for 3 days. After treatment, the number of viable cells was determined using the MTS assay (CellTiter 96® AQueous Assay; Promega, Madison, WI). In brief, 20 ul of MTS solution was added to each well and cells were incubated for 1 h. The absorbance at 490 nm was measured with an ELISA microplate reader. Each experiment was performed in quadruplicate and repeated at least three times.
- 30 Flow Cytometric Analysis. Cells were seeded in 25 ml flasks in conditions as described above. Following treatment, trypsinization and cell counting, LNCaP

cells (1x10⁶) were suspended in 1 mL PBS and incubated with 0.2 mL 0.4 % Triton X-100 for 5 min at R/T in the presence of 50 μL of propidium iodide solution (50 μg/mL) and 20 μL of ribonuclease (10 mg/mL). DNA content per cell was measured by flow cytometry using an FACScalibur flow cytometer and CellQuest software (Becton Dickinson, Franklin Lakes, NJ). Statistical analysis was performed on 10,000 events per sample.

RT-PCR. Total cellular RNA was isolated from LNCaP, DU145 or PC-3 cells using the Trizol reagent (LifeTechnologies, Inc.). First-strand cDNA was 10 synthesized from 5 µg of RNA with the cDNA preamplification system (Life Technologies, Inc.) using SuperScript II reverse transcriptase and an oligo(dT) primer. This was used as the template in standard PCR reactions using Amplitaq DNA polymerase (Perkin-Elmer Life Sciences, Boston, MA). Amplification products were analyzed on 2% TAE agarose gels made with 15 MetaPhor agarose (FMC BioProducts, Rockland, ME) and photographed under UV illumination. DNA ladders of 25 and 100 bp (Life Technologies, Inc.) were used as size standards. Primers were designed based on the human sPLA2-IIA mRNA (NM_000300.2) deposited in the GenBank database (National Center for Biotechnology Information, Bethesda, MD) and are as follows: 20 forward: 5'-TTTGTCACCCAAGAACTCTTAC-3', 5'reverse: GGGAGGGAGGGTATGAGA-3'.

Tissues. Normal prostate was obtained from brain-dead organ donors as described previously (Chetcuti et al., (2001) Cancer Research, 61:6331-6334).

Benign prostatic hyperplasia (BPH) was obtained from transurethral resection of the prostate. Cancer tissue was from radical prostatectomy. Informed consent was obtained from patients, and the study protocol was approved by the Central Sydney Area Health Service Ethics Review Committee.

30 Immunohistochemistry. Prostate tissues (normal, benign hyperplastic and cancer) were all fixed in 10% formaldehyde solution for <24 hours and paraffin

embedded. Tissue sections (5 μm) were incubated for 1 hour at 37°C after microwave antigen retrieval with the appropriate primary antibody diluted in 1% goat serum. Biotinylated goat anti-rabbit or mouse IgG, diluted 1/200 in 1% normal goat serum, was used as the secondary antibody. The signal was amplified using the avidin-biotin-peroxidase complex system (Vector Laboratories) and visualised using the liquid DAB substrate-chromogen system (Dako). Sections were counterstained with hematoxylin. Negative isotype and method controls were performed for each sample by substituting the primary antibody with rabbit IgG and 1% goat serum, respectively.

10

Image Analysis. Immunoperoxidase staining was considered positive and specific when the intensity of with the post-immune IgG clearly exceeded that observed with the preimmune IgG (isotype control) and with no IgG (method control). Specific staining was graded for the percentage of immunopositive normal or cancer epithelial cells as described (Kommoss, 1989 Anal. Quant. Cytol. Histol. 11:298-306). Briefly, the percentage of positive-stained normal, or cancerous epithelial cells per slide was stratified into three groups: group 1, 0-33%; group 2, 34-66%; and group 3, 67-100%. Zero represented no cells with specific staining.

20

Statistical Analysis. The Number Cruncher Statistical System (NCSS, Kaysville, UT) was used for statistical analysis. Data were analyzed by one-way ANOVA and correlation coefficient as appropriate. A two-tailed P value <0.05 was considered significant.

2

Example 1: sPLA₂-IIA is Induced in Prostate Cancer Cells and Constitutively Activated in AIPC.

We searched the database of Serial Analysis of Gene Expression (SAGE) to determine the steady state mRNA levels of individual PLA₂ enzymes in prostate cancer. The cDNA libraries used for SAGE was PR317 normal prostate and

PR317 prostate cancer, respectively (www.ncbi.nlm.nih.gov/SAGE), as both are derived from microdissected prostate tissues. We found that sPLA2-IIA mRNA was 22 times higher in prostate cancer than normal prostate, whereas other members were either not expressed in the prostate libraries or 5 unchanged in cancer. To verify the SAGE result and extend the expression analysis to androgen-independent prostate cancer (AIPC), we examined sPLA2-IIA expression by immunohistochemistry in prostate cancer tissues from patients treated with androgen-ablation therapy for 3 months prior to radical prostatectomy. Cancer cells remaining in specimens following androgen-10 ablation therapy are regarded as being closest to AIPC, although they are confined within the prostate. Cancer specimens from patients undergoing radical prostatectomy without androgen ablation therapy served as the control. Two antibodies were used for immunohistochemistry, and both showed the same expression pattern. In the control group, (N=50), there was weak and 15 patchy staining in benign glands (Fig. 1A and C.) adjacent to cancer cells and extensive staining in cancer cells (Fig. 1 C.). In the androgen-ablated group (N=25), benign glands lost their staining, whereas AIPC cells maintained sPLA2-IIA expression (Fig. 1 B and C). We also found that the extent of sPLA2-IIA staining is positively correlated with the tumour grade and post-operative 20 PSA level (data not shown). The chromosomal location of sPLA2-IIA (1p35.1-36) was also found to overlap with a prostate cancer susceptibility locus CAPB (Gibbs et al (1999) Am. J. Hum. Genet. 64:776-787). No difference was found in immunohistochemical staining for $cPLA_{2}$ - α between normal and cancer cells irrespective of androgen status (data not shown).

25

The lack of sPLA₂–IIA expression in benign glands following androgen deprivation suggests that expression of sPLA₂–IIA gene requires androgens. To verify that, we searched the 5'- flanking region of the sPLA₂–IIA gene using MatInspector Release 5.3 (Genomatix), and found an androgen response element (ARE) GAGGTAAATGGTATTCTC from -546 to -527. Secondly, we treated the androgen responsive human prostate cancer cell line, LNCaP, with

WO 2004/064822 PCT/AU2003/000719

32

various doses of androgens and measured sPLA₂–IIA mRNA and protein levels by RT-PCR and ELISA (data not shown). Indeed, there was an increase in the level of sPLA₂–IIA transcript following 1 nM androgen treatment. In contrast, we could not find an ARE within 3 kb of genomic DNA in the 5-flanking region of the cPLA₂-α gene. Androgen treatment had no effect on cPLA₂-α mRNA and protein levels (data not shown). Together, these findings indicate that sPLA₂-IIA, but not cPLA₂-α expression is normally dependent on androgens and in AIPC sPLA₂-IIA expression becomes androgen-independent *via* an as yet unknown mechanism.

10

Example 2: Oncogenic Action of sPLA2-IIA in Prostate Cancer Cells.

To examine the biological relevance of sPLA₂-IIA to prostate cancer cell growth, we treated LNCaP cells with increasing doses of human recombinant sPLA₂-IIA and monitored cell growth. LNCaP is the only available prostate cancer cell line that expresses both the androgen receptor and PSA. Exogenously-added sPLA₂-IIA at doses as low as 1 nM, consistently and dose-dependently stimulated LNCaP cell growth as measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethylphenyl)-2-(4-sulphophenyl)-2H-

- 20 tetrazolium (MTS) assay (Fig. 2A). In contrast addition of an activity-dead sPLA₂-IIA mutant protein H₄₈Q, showed no stimulation relative to untreated cells (Fig. 2A) indicating that enzyme activity is essential for the growthstimulatory effect.
- We have previously shown that human sPLA₂-IIA is dose-dependently inhibited by a pentapeptide sequence comprising residues 70-74 of the native sPLA₂-IIA protein (⁷⁰FLSYK⁷⁴) (Tseng, A., et al., (1996) J. Biol. Chem. 271:23992-23998). Because of the inherent flexibility of the linear peptide sequence, inhibition was weak in *in vitro* activity assays. We have recently designed two novel cyclic peptides (Church, W.B. et al.), cFLSYR and a cyclic peptide where F and Y are substituted with 2-naphthylalanine (c(2NapA)LS(2NapA)R). Both have shown

significant improvement in potency over linear peptides. The potent stimulatory effect of exogenous sPLA₂-IIA on prostate cancer cell number was completely blocked by the sPLA₂-IIA inhibitor, cFLSYR (Fig. 2B) at all concentrations tested.

5

We next used flow cytometric analysis to determine how sPLA₂-IIA affects the distribution of LNCaP cells in different phases of the cell cycle. In sPLA₂-IIA containing medium, the proportion of LNCaP cells in the G1 phase decreased from 74% to 62% with corresponding increase of cells in G2/M phase in comparison to untreated cells (Fig. 2C). In the presence of both sPLA₂-IIA and its inhibitor (cFLSYR), the proportion of cells in G1 and G2 phase returned to basal levels (Fig. 2C). These results establish the biological importance of the sPLA₂-IIA enzyme activity in prostate cancer cells and demonstrate that sPLA₂-IIA-induced cell growth can be attributed at least partly to an increased proportion of cells entering G2/M phase from G1 phase.

Example 3: Oncogenic Action of sPLA₂-IIA requires cPLA₂-α activity.

Currently, two models are proposed to explain the action of sPLA₂ on eicosanoid production (Murakami, M., Kudo, I. (2002) J. Biochem. 131:285-292). One is the direct cleavage of membrane phospholipids. In this model, sPLA₂ binds directly to plasma membrane phospholipids and the released arachidonic acid serves as a substrate to produce eicosanoids. Lysophospholipids and/or eicosanoid products of arachidonic acid metabolism mediate indirect activation of the endogenous cPLA₂-α *via* mobilisation of calcium. The enhanced cPLA₂-α activity can in turn result in enhanced production of eicosanoids. The second model is indirect modulation of intracellular eicosanoid pathways *via* cell surface GPI-linked heparan sulphate proteoglycan receptors. The internalised sPLA₂ supplies arachidonic acid to downstream enzymes either directly, or indirectly via activation of cPLA₂-α through mitogen activated protein (MAP) kinase-mediated phosphorylation.

To determine if sPLA₂-IIA-induced cell proliferation depends on cPLA₂-α, we treated LNCaP cells with various doses of selective cPLA₂ inhibitor, pyrrolidine-1 (Ghomashchi, F. et al. (2001) Biochim. Biophys. Acta Biomembranes 2:160-166) with or without a constant effective dose of sPLA₂-IIA (1 nM). Blockade of cPLA₂-α abolishes sPLA₂-IIA-induced cell growth completely (Fig. 3), demonstrating that cPLA₂-α activation is necessary for sPLA₂-IIA-dependent cell proliferation. In the absence of sPLA₂-IIA, the cPLA₂-α inhibitor had no effect on cell growth, suggesting that cPLA₂-α does not promote cell proliferation independently in LNCaP cells (see legend Fig. 3).

Example 4: sPLA2-IIA Inhibitors Suppress Endogenous Proliferation.

Based on our finding that the growth-promoting sPLA₂-IIA is constitutively expressed in AIPC we have considered the potential of sPLA₂-IIA as a target for treatment of AIPC. We reason that a better outcome can be achieved with the PLA₂ inhibitor than with a COX inhibitor alone because the latter suppresses the production of prostaglandins only.

To test the effect of blocking endogenous sPLA₂-IIA on cell growth, we firstly determined the basal mRNA levels of sPLA₂-IIA in 3 human prostate cancer cell lines. The androgen-independent cell lines PC-3 and DU145 cells were included in the study to also exclude a possible general toxicity of the inhibitors. mRNA encoding sPLA₂-IIA was undetectable in DU-145 compared with LNCaP and PC-3 cells (Fig 4A). We then tested the effect of individual inhibitors cFLSYR and c(2Nap)LS(2Nap)R on cell growth over a range of doses (1-100 nM). The proliferation of LNCaP and PC-3 cells was significantly decreased, and the smallest effective dose was 1 nM for both inhibitors (Fig. 4B). In contrast, neither of the inhibitors had an effect on DU145, presumably due to the lack of endogenous sPLA₂-IIA. The low but reffective dosage and its

specificity for cell lines containing endogenous sPLA₂-IIA only, indicate that non-specific cell toxicity is not likely to explain the inhibitory effect.

In summary, the normally androgen-induced sPLA₂–IIA gene expression is constitutively activated in androgen-independent prostate cancer. Exogenously added sPLA₂–IIA promotes prostate cell proliferation through its enzyme product and cPLA₂. A better therapeutic outcome is likely to be achieved with an sPLA₂ inhibitor in prostate cancer including the form of AIPC.

All publications mentioned in the above specification are herein incorporated in their entirety by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are apparent to those skilled in molecular biology or related fields are intended to be within the scope of the invention.

CLAIMS:

- 1. A method of inhibiting or reducing the proliferation of prostate cancer cells, the method comprising administering to the cells a PLA₂ inhibitor.
- 2. A method for the treatment of prostate cancer, the method comprising administering to a subject in need thereof a PLA₂ inhibitor.
- 3. A method according to claim 1 or claim 2 wherein the prostate cancer cells are androgen independent prostate cancer (AIPC) cells.
 - 4. A method according to any one of claims 1 to 3, wherein the PLA_2 inhibitor is a $cPLA_2$ - α inhibitor.
- 15 5. A method according to any one of claims 1 to 3, wherein the PLA₂ inhibitor is an sPLA₂-IIA inhibitor.
- A method according to claim 5, wherein the PLA₂ inhibitor is a conformationally constrained molecule derived from a peptide consisting
 essentially of amino acid residues 70-74 of a human sPLA₂-IIA protein, or the equivalent residues in other sPLA₂ proteins.
 - 7. A method according to claim 6 wherein the conformationally constrained molecule is a cyclic molecule.
 - 8. A method according to claim 6 wherein the conformationally constrained molecule is a cyclic peptide or derivative thereof.
- 9. A method according to claim 8, wherein the conformationally constrained30 peptide is a cyclic peptide of the following formula:

A1-A2-A3-A4-A5

in which

25

A1 is F or Y or W or 2Nap

A2 is L or I
A3 is S or T
A4 is F or Y or W or 2Nap
A5 is R or K.

5

- 10. A method according to claim 9, wherein the peptide is selected from the group consisting of cFLSYK, cFLSYR and c(2NapA)LS(2NapA)R.
- 11. A method according to any one of claims 1 to 10, wherein a cPLA₂-α
 10 inhibitor is administered in conjunction with an sPLA₂-IIA inhibitor.
 - 12. A method for detecting prostate cancer or a metastases thereof in a subject, said method comprising:

determining the level of PLA2 mRNA expressed in a test sample from said subject; and

comparing the level of PLA2 mRNA determined at (i) to the level of PLA2.mRNA expressed in a comparable sample from a healthy or normal individual,

wherein a level of PLA₂ mRNA at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of a cancer cell in said subject.

- 13. A method for detecting prostate cancer or a metastases thereof in a subject, said method comprising:
- 25 determining the level of a PLA₂ polypeptide in a test sample from said subject; and

comparing the level of PLA₂ polypeptide determined at (i) to the level of said PLA₂ polypeptide in a comparable sample from a healthy or normal individual,

wherein a level of said PLA₂ polypeptide at (i) that is enhanced in the test sample relative to the comparable sample from the normal or healthy individual is indicative of the presence of a cancer cell in said subject.

- 5 14. A method of assessing the predisposition of a subject to prostate cancer, the method comprising the step of determining the presence of a polymorphism or an epigenetic change in a PLA₂ gene of the subject.
- 15. A method according to any one of claims 12 to 14 wherein the prostate cancer cells are androgen independent prostate cancer (AIPC) cells.
 - 16. A method according to any one of claims 12 to 14, wherein the PLA₂ is $cPLA_2$ - α .
- 15 17. A method according to any one of claims 12 to 14, wherein the PLA₂ is sPLA₂-IIA.

DT09 Rec'd PCT/PTO 0 7 DEC 2004

WO 2004/064822

PCT/AU2003/000719

|) | | | | SEQUENCE | LISTING | | |
|----|----------------------------------|-------------------------|--------------|--------------|------------|-------------|------------|
| | <110> | Scot | t, Kieran | | | | |
| 5 | <120> | Meth | od of inhib | oiting prost | ate cancer | cell prolif | eration |
| | <130> | 5015 | 43 | | | | |
| 10 | <150> <151> | PS28 2002 | 26 -06-07 | | | | |
| | <160> | 4 | | | | | |
| 15 | <170> | Pate | ntIn versio | on 3.1 | | | |
| | <210> <211> <212> <213> | 1 997 DNA Homo | sapiens | | | | |
| 20 | <400> | 1 | | | | | |
| | | - | gagcaacaga | tccagggagc | attcacctgc | cctgtctcca | aacagcctto |
| 25 | tgcctc 120 | acct | acccccaacc | tcccagaggg | agcagctatt | taaggggagc | aggagtgcaç |
| 30 | aacaaa 180 | caag | acggcctggg | gatacaactc | tggagtcctc | tgagagagcc | accaaggagg |
| 00 | agcagg | ggag | cgacggccgg | ggcagaagtt | gagaccaccc | agcagaggag | ctaggccagt |
| 35 | ccatct 300 | gcat | ttgtcaccca | agaactctta | ccatgaagac | cctcctactg | ttggcagtga |
| | tcatga 360 | tctt | tggcctactg | caggcccatg | ggaatttggt | gaatttccac | agaatgatca |
| 40 | agttga 420 | cgac | aggaaaggaa | gccgcactca | gttatggctt | ctacggctgc | cactgtggc |
| 45 | tgggtg 480 | gcag | aggatecece | aaggatgcaa | cggatcgctg | ctgtgtcact | catgactgtt |
| 10 | gctaca 540 | aacg | tctggagaaa | cgtggatgtg | gcaccaaatt | tctgagctac | aagtttagca |
| 50 | actcgg 600 | ggag | cagaatcacc | tgtgcaaaac | aggactcctg | cagaagtcaa | ctgtgtgagt |
| | gtgata 660 | aggc | tgctgccacc | tgttttgcta | gaaacaagac | gacctacaat | aaaaagtac |
| 55 | agtact 720 | attc | caataaacac | tgcagaggga | gcacccctcg | ttgctgagtc | ccctcttcc |

tggaaacctt ccacccagtg ctgaatttcc ctctctcata ccctccctcc ctaccctaac caagtteett ggccatgeag aaagcateee teacceatee tagaggeeag geaggageee 5 840 ttctataccc acccagaatg agacatccag cagatttcca gccttctact gctctcctcc 10 acctcaactc cgtgcttaac caaagaagct gtactccggg gggtctcttc tgaataaagc aattagcaaa aaaaaaaaa aaaaaaaa aaaaaaa 15 <210> 2 <211> 2875 <212> DNA 20 <213> Homo sapiens <400> 2 gaattctccg gagctgaaaa aggatcctga ctgaaagcta gaggcattga ggagcctgaa 25 gattctcagg ttttaaagac gctagagtgc caaagaagac tttgaagtgt gaaaacattt cctgtaattg aaaccaaaat gtcatttata gatccttacc agcacattat agtggagcac 30 cagtattccc acaagtttac ggtagtggtg ttacgtgcca ccaaagtgac aaagggggcc 35 tttggtgaca tgcttgatac tccagatccc tatgtggaac tttttatctc tacaacccct gacagcagga agagaacaag acatttcaat aatgacataa accctgtgtg gaatgagacc 40 tttgaattta ttttggatcc taatcaggaa aatgttttgg agattacgtt aatggatgcc aattatgtca tggatgaaac tctagggaca gcaacattta ctgtatcttc tatgaaggtg 45 ggagaaaaga aagaagttcc ttttattttc aaccaagtca ctgaaatggt tctagaaatg 50 tctcttgaag tttgctcatg cccagaccta cgatttagta tggctctgtg tgatcaggag aagactttca gacaacagag aaaagaacac ataagggaga gcatgaagaa actcttgggt 55 ccaaagaata gtgaaggatt gcattctgca cgtgatgtgc ctgtggtagc catattgggt

| | tcaggtgggg 780 | gtttccgagc | catggtggga | ttctctggtg | tgatgaaggc | attatacgaa |
|----|--------------------|------------|------------|------------|------------|------------|
| 5 | tcaggaattc 840 | tggattgtgc | tacctacgtt | gctggtcttt | ctggctccac | ctggtatatg |
| 10 | tcaaccttgt 900 | attctcaccc | tgattttcca | gagaaagggc | cagaggagat | taatgaagaa |
| 10 | ctaatgaaaa 960 | atgttageca | caatcccctt | ttacttctca | caccacagaa | agttaaaaga |
| 15 | tatgttgagt 1020 | ctttatggaa | gaagaaaagc | tctggacaac | ctgtcacctt | tactgacato |
| | tttgggatgt 1080 | taataggaga | aacactaatt | cataatagaa | tgaatactac | tctgagcagt |
| 20 | ttgaaggaaa 1140 | aagttaatac | tgcacaatgc | cctttacctc | ttttcacctg | tcttcatgto |
| 25 | aaacctgacg 1200 | tttcagagct | gatgtttgca | gattgggttg | aatttagtcc | atacgaaatt |
| | ggcatggcta 1260 | aatatggtac | ttttatggct | cccgacttat | ttggaagcaa | attttttatg |
| 30 | ggaacagtcg 1320 | ttaagaagta | tgaagaaaac | cccttgcatt | tcttaatggg | tgtctgggg |
| | agtgcctttt 1380 | ccatattgtt | caacagagtt | ttgggcgttt | ctggttcaca | aagcagaggo |
| 35 | tccacaatgg 1440 | aggaagaatt | agaaaatatt | accacaaagc | atattgtgag | taatgatago |
| 40 | tcggacagtg 1500 | atgatgaatc | acacgaaccc | aaaggcactg | aaaatgaaga | tgctggaagt |
| •• | gactatcaaa 1560 | gtgataatca | agcaagttgg | attcatcgta | tgataatggc | cttggtgagt |
| 45 | gattcagctt 1620 | tattcaatac | cagagaagga | cgtgctggga | aggtacacaa | cttcatgctç |
| | ggcttgaatc 1680 | tcaatacatc | ttatccactg | tctcctttga | gtgactttgc | cacacagga |
| 50 | tcctttgatg 1740 | atgatgaact | ggatgcagct | gtagcagatc | ctgatgaatt | tgagcgaata |
| 55 | tatgageete 1800 | tggatgtcaa | aagtaaaaag | attcatgtag | tggacagtgg | gctcacatt |
| | aacctgccgt 1860 | atcccttgat | actgagacct | cagagagggg | ttgatctcat | aatctcctt |

WO 2004/064822 PCT/AU2003/000719

43

gacttttctg caaggccaag tgactctagt cctccgttca aggaacttct acttgcagaa aagtgggcta aaatgaacaa gctccccttt ccaaagattg atccttatgt gtttgatcgg gaagggctga aggagtgcta tgtctttaaa cccaagaatc ctgatatgga gaaagattgc 10 ccaaccatca tccactttgt tctggccaac atcaacttca gaaagtacaa ggctccaggt gttccaaggg aaactgagga agagaaagaa atcgctgact ttgatatttt tgatgaccca 15 gaatcaccat tttcaacctt caattttcaa tatccaaatc aagcattcaa aagactacat 2220 20 gatcttatgc acttcaatac tctgaacaac attgatgtga taaaagaagc catggttgaa agcattgaat atagaagaca gaatccatct cgttgctctg tttcccttag taatgttgag 25 gcaagaaga't ttttcaacaa ggagtttcta agtaaaccca aagcatagtt catgtactgg 2400 aaatggcagc agtttctgat gctgaggcag tttgcaatcc catgacaact ggatttaaaa 30 gtacagtaca gatagtcgta ctgatcatga gagactggct gatactcaaa gttgcagtta 35 cttagctgca tgagaataat actattataa gttaggtgac aaatgatgtt gattatgtaa ggatatactt agctacattt tcagtcagta tgaacttcct gatacaaatg tagggatata 40 tactgtattt ttaaacattt ctcaccaact ttcttatgtg tgttcttttt aaaaattttt tttcttttaa aatatttaac agttcaatct caataagacc tcgcattatg tatgaatgtt 45 2760 attcactgac tagatttatt cataccatga gacaacacta tttttattta tatatgcata 50 tatatacata catgaaataa atacatcaat ataaaaataa aaaaaaacgg aattc 2875 <210> 3 55 <211> 144 <212> PRT <213> Homo sapiens

44

| | <400 |)> 3 | 3 | | | | | | | | | | | | | |
|----|------------------------------|--------------|-------------------------|------------|-----------|-----------|------------|------------|------------|-----------|-----------|------------|------------|------------|-----------|-----------|
| 5 | Met 1 | Lys | Thr | Leu | Leu 5 | Leu | Leu | Ala | Val | Ile 10 | Met | Ile | Phe | Gly | Leu 15 | Leu |
| 10 | Gln | Ala | His | Gly 20 | Asn | Leu | Val | Asn | Phe 25 | His | Arg | Met | Ile | Lys 30 | Leu | Thr |
| | Thr | Gly | Lys 35 | Glu | Ala | Ala | Leu | Ser 40 | Tyr | Gly | Phe | Tyr | Gly 45 | Cys | His | Cys |
| 15 | Gly | Val 50 | Gly | Gly | Arg | Gly | Ser 55 | Pro | Lys | Asp | Ala | Thr 60 | Asp | Arg | Cys | Cys |
| 20 | Val 65 | Thr | His | Asp | Cys | Cys 70 | Tyr | Lyż | Arg | Leu | Glu 75 | Lys | Arg | Gly | Cys | Gly 80 |
| 25 | Thr | Lys | Phe | Leu | Ser 85 | Tyr | Lys | Phe | Ser | Asn 90 | Ser | Gly | Ser | Arg | Ile 95 | Thr |
| 30 | Cys | Ala | Lys | Gln 100 | Asp | Ser | Cys | Arg | Ser 105 | Gln | Leu | Cys | Glu | Cys 110 | Asp | Lys |
| | Ala | Ala | Ala 115 | Thr | Суз | Phe | Ala | Arg 120 | Asn | Lys | Thr | Thr | Tyr 125 | Asn | Lys | Lys |
| 35 | Tyr | Gln 130 | Tyr | Tyr | Ser | Asn | Lys 135 | His | Суѕ | Arg | Gly | Ser 140 | Thr | Pro | Arg | Cys |
| 40 | <210 <210 <210 <210 | L> ' 2> 1 | 4 749 PRT Homo | sap | iens | | | | | | | | | | | |
| 45 | <40 |)> · | 4 | | | | | | | | | | | | | |
| | Met 1 | Ser | Phe | Ile | Asp 5 | Pro | Tyr | Gln | His | Ile 10 | Ile | Val | Glu | His | Gln 15 | Tyr |
| 50 | Ser | His | Lys | Phe 20 | Thr | Val | Val | Val | Leu 25 | Arg | Ala | Thr | Lys | Val 30 | Thr | Lys |

Gly Ala Phe Gly Asp Met Leu Asp Thr Pro Asp Pro Tyr Val Glu Leu 35 40 45

WO 2004/064822 PCT/AU2003/000719

| | Phe | Ile 50 | Ser | Thr | Thr | Pro | Asp 55 | Ser | Arg | Lys | Arg | Thr 60 | Arg | His | Phe | Asn |
|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
| 5 | Asn 65 | Asp | Ile | Asn | Pro | Val 70 | Trp | Asn | Glu | Thr | Phe 75 | Glu | Phe | Ile | Leu | Asp 80 |
| 10 | Pro | Asn | Gln | Glu | Asn 85 | | Leu | Glu | Ile | Thr 90 | Leu | Met | Asp | Ala | Asn 95 | Tyr |
| 15 | Val | Met - | Asp | Glu 100 | Thr | Leu | Gly | Thr | Ala 105 | Thr | Phe | Thr | Val | Ser 110 | Ser | Met |
| 20 | Lys | Val | Gly 115 | Glu | Lys | Lys | Glu | Val 120 | Pro | Phe | Ile | Phe | Asn 125 | Gln | Val | Thr |
| | Glu | Met 130 | | Leu | Glu | Met | Ser 135 | Leu | Glu | Val | Суз | Ser 140 | Cys | Pro | Asp | Leu |
| 25 | Arg 145 | Phe | Ser | Met | Ala | Leu 150 | Cys | Asp | Gln | Glu | Lys 155 | Thr | Phe | Arg | Gln | Gln 160 |
| 30 | Arg | Lys | Glu | His | Ile 165 | Arg | Glu | Ser | Met | Lys 170 | | Leu | Leu | Gly | Pro 175 | Lys |
| 35 | Asn | Ser | Glu | Gly 180 | Leu | His | Ser | Ala | Arg 185 | Asp | Val | Pro | Val | Val 190 | Ala | Ile |
| 4 0 | Leu | Gly | Ser 195 | Gly | Gly | Gly | Phe | Arg 200 | Ala | Met | Val | Gly | Phe 205 | Ser | Gly | Val |
| | Met | Lys 210 | Ala | Leu | Tyr | Glu | Ser 215 | Gly | Ile | Leu | Asp | Cys 220 | Ala | Thr | Tyr | Val |
| 45 | Ala 225 | Gly | Leu | Ser | Gly | Ser 230 | Thr | Trp | Tyr | Met | Ser 235 | Thr | Leu | Tyr | Ser | His 240 |
| 50 | Pro | Asp | Phe | Pro | Glu 245 | Lys | Gly | Pro | Glu | Glu 250 | Ile | Asn | Glu | Glu | Leu 255 | Met |
| 55 | Lys | Asn | Val | Ser 260 | His | Asn | Pro | Leu | Leu 265 | Leu | Leu | Thr | Pro | Gln 270 | Lys | Val |

| | : | Lys | Arg | Tyr 275 | Val | Glu | Ser | Leu | Trp 280 | Lys | Lys | Lys | Ser | Ser 285 | Gly | Gln | Pro |
|------|---|------------|------------|------------|------------|------------|------------|------------|--------------|------------|------------|------------|------------|------------|------------|------------|------------|
| 5 | , | Val | Thr 290 | Phe | Thr | Asp | Ile | Phe 295 | | Met | Leu | Ile | Gly 300 | Glu | Thr | Leu | Ile |
| · 10 | | His 305 | Asn | Arg | Met | Asn | Thr 310 | Thr | Leu | Ser | Ser | Leu 315 | Lys | Glu | ГÀЗ | Val | Asn 320 |
| 15 | • | Thr | Ala | Gln | Cys | Pro 325 | Leu | Pro | Leu | Phe | Thr 330 | Cys | Leu | His | Val | Lys 335 | Pro |
| 20 | : | Asp | Val | Ser | Glu 340 | Leu | Met | Phe | Ala | Asp 345 | Trp | Val | Glu | Phe | Ser 350 | Pro | Туг |
| 20 | • | Glu | Ile | Gly 355 | Met | Ala | Lys | Tyr | Gly 360 | Thr | Phe | Met | Ala | Pro 365 | Asp | Leu | Phe |
| 25 | • | Gly | Ser 370 | Lys | Phe | Phe | Met | Gly 375 | Thr | Val | Val | Lys | Lys 380 | Tyr | Glu | Glu | Asn |
| 30 | | Pro 385 | Leu | His | Phe | Leu | Met 390 | Gly | V <u>a</u> l | Trp | Gly | Ser 395 | Ala | Phe | Ser | Ile | Leu 400 |
| 35 | | Phe | Asn | Arg | Val | Leu 405 | Gly | Val | Ser | Gly | Ser 410 | Gln | Ser | Arg | Gly | Ser 415 | Thr |
| 40 | | Met | Glu | Glu | Glu 420 | Leu | Glu | Asn | Ile | Thr 425 | Thr | Lys | His | Ile | Val 430 | Ser | Asn |
| 40 | | Asp | Ser | Ser 435 | Asp | Ser | Asp | Asp | Glu 440 | Ser | His | Glu | Pro | Lys 445 | Gly | Thr | Glu |
| 45 | | Asn | Glu 450 | Asp | Ala | Gly | Ser | Asp 455 | Tyr | Gln | Ser | Asp | Asn 460 | Gln | Ala | Ser | Trp |
| 50 | | Ile 465 | His | Arg | Met | Ile | Met 470 | Ala | Leu | Val | Ser | Asp 475 | Ser | Ala | Leu | Phe | Asn 480 |
| 55 | | Thr | Arg | Glu | Gly | Arg 485 | Ala | Gly | Lys | Val | His 490 | Asn | Phe | Met | Leu | Gly 495 | Leu |
| | | Asn | Leu | Asn | Thr | Ser | Tyr | Pro | Leu | Ser | Pro | Leu | Ser | Asp | Phe | Ala | Thr |

| | | | | 500 | | | | | 505 | | | | | E10 | | |
|----|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------------|------------|------------|
| | | | | 300 | | | | | 303 | | | | | 510 | | |
| 5 | Gln | Asp | Ser 515 | Phe | Asp | Asp | Asp | Glu 520 | Leu | Asp | Ala | Ala | Val 525 | Ala | Asp | Pro |
| 10 | Asp | Glu 530 | Phe | Glu | Arg | Ile | Tyr 535 | Glu | Pro | Leu | Asp | Val 540 | Lys | Ser | Lys | Lys |
| | Ile 545 | His | Val | Val | Asp | Ser 550 | Gly | Leu | Thr | Phe | Asn 555 | Leu | Pro | Tyr | Pro | Leu 560 |
| 15 | Ile | Leu | Arg | Pro | Gln 565 | Arg | Gly | Val | Asp | Leu 570 | Ile | Ile | Ser | Phe _. | Asp 575 | Phe |
| 20 | Ser | Ala | Arg | Pro 580 | Ser | Asp | Ser | Ser | Pro 585 | Pro | Phe | Ьуs | Glu | Leu 590 | Leu | Leu |
| 25 | Ala | Glu | Lys 595 | Trp | Ala | Lys | Met | Asn 600 | Lys | Leu | Pro | Phe | Pro 605 | Lys | Ile | Asp |
| 30 | Pro | Tyr 610 | Val | Phe | Asp | Arg | Glu 615 | Gly | Leu | Lys | Glu | Cys 620 | Tyr | Val | Phe | Lys |
| | Pro 625 | Lys | Asn | Pro | Asp | Met 630 | Glu | Ļys | Asp | Cys | Pro 635 | Thr | Ile | Ile | His | Phe 640 |
| 35 | Val | Leu | Ala | Asn | 11e 645 | Asn | Phe | Arg | Lys | Tyr 650 | Ъуз | Ala | Pro | Gly | Val 655 | Pro |
| 40 | Arg | Glu | Thr | Glu 660 | Glu | Glu | Lys | Glu | Ile 665 | Ala | Asp | Phe | Asp | Ile 670 | Phe | Asp |
| 45 | Asp | Pro | Glu 675 | Ser | Pro | Phe | Ser | Thr 680 | Phe | Asn | Phe | Gln | Tyr 685 | Pro | Asn | Gln |
| 50 | Ala | Phe 690 | ГЛS | Arg | Leu | His | Asp 695 | Leu | Met | His | Phe | Asn 700 | Thr | Leu | Asn | Asn |
| | Ile 705 | Asp | .Val | Ile | Lys | Glu 710 | Ala | Met | Val | Glu | Ser 715 | Ile | Glu | Tyr | Arg | Arg 720 |
| 55 | Gln | Asn | Pro | Ser | _ | Cys | | Val | Ser | Leu 730 | | Asn | Val | Glu | Ala 735 | Arg |

PCT/AU2003/000719


· 48


Arg Phe Phe Asn Lys Glu Phe Leu Ser Lys Pro Lys Ala 740 745


PCT/AU2003/000719

1/4

Figure 1










PCT/AU2003/000719

2/4

Figure 2








PCT/AU2003/000719

3/4

Figure 3



Colored Land


WO 2004/064822

PCT/AU2003/000719


4/4

Figure 4

A.



В.



INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU03/00719

| | | | PC17AU03/0 | 0/19 |
|---|--|--------------------|---|-----------------------|
| Α | CLASSIFICATION OF SUBJECT M | IATTE | R | |
| Int. Cl. 7: | A61 K 31/16, 31/445, 31/505, 35/3 | 6, 38/4 | 3, 47/10, 47/14, 31/40, A61P 35/00, 35/04 | |
| According to | International Patent Classification (IPC) | or to be | oth national classification and IPC | |
| в | FIELDS SEARCHED | | | |
| Minimum doc | umentation searched (classification system fol | llowed b | y classification symbols) | |
| Documentation | n searched other than minimum documentatio | n to the | extent that such documents are included in the fields search | hed |
| Electronic data Derwent W | a base consulted during the international search PI, MEDLINE. Key words: prostate of | h (name | of data base and, where practicable, search terms used) sPLA2-IIA, cPLA2-\(\pi\), inhibitor, PLA2 mRNA, | PLA ₂ . |
| C. | DOCUMENTS CONSIDERED TO BE R | ELEVA | NT | |
| Category* | Citation of document, with indication, | where a | appropriate, of the relevant passages | Relevant to claim No. |
| х | WO 98/05349 A (SMITHKLINE I Whole document | BEECH | IAM CORP.), 12 February 1998 | 1-17 |
| x | US 5 942 402 A (SCHMIDT et al) Whole document | , 24 Aı | igust 1999 | 1-17 |
| P,X | WO 03/014082 A (ELI LILLY & 0 Page 3, paragraph 4, page 7 lines 1 | CO), 20 2 and o | February 2003 Claims 16 and 17 | 1-17 |
| X F | Further documents are listed in the con | ntinuat | ion of Box C X See patent family ann | ex · |
| "A" docume which i relevan "E" earlier | categories of cited documents: ent defining the general state of the art is not considered to be of particular ce application or patent but published on or e international filing date | "T" | later document published after the international filing de and not in conflict with the application but cited to unde or theory underlying the invention document of particular relevance; the claimed invention considered novel or cannot be considered to involve an when the document is taken alone | rstand the principle |
| claim(s publica reason ("O" docume | ent which may throw doubts on priority) or which is cited to establish the tion date of another citation or other special (as specified) ent referring to an oral disclosure, use, ion or other means | "Y" | document of particular relevance; the claimed invention considered to involve an inventive step when the docum with one or more other such documents, such combinati a person skilled in the art document member of the same patent family | ent is combined |
| "P" docume | ent published prior to the international filing taler than the priority date claimed | | | |
| | rater than the profity date claimed | | Date of mailing of the international search report | |
| 26 June 2003 | | | <u>-</u> | 1 4 AUG 2003 |
| | ing address of the ISA/AU | | Authorized officer | · · · · · · |
| PO BOX 200, V E-mail address: | I PATENT OFFICE WODEN ACT 2606, AUSTRALIA pct@ipaustralia.gov.au (02) 6285 3929 | | Steven Chew Telephone No: (02) 6283 2248 | |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU03/00719

| | FC1/A005/00 | 127 |
|-------------|---|-----------------------|
| C (Continua | tion). DOCUMENTS CONSIDERED TO BE RELEVANT | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| · X | EP 1 300 159 A (SHIONOGI & CO., LTD), 9 April 2003 Whole document | 1-3 |
| x | ATTIGA, FA. et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumour cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Research, August 2000, vol. 60, pages 4629-4637 Whole document | 1-3 |
| x | DE SOUZA, PL et al. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. British Journal of Cancer, 1997, vol.75(11), pages 1593-1600 Whole document | 1-3 |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No. PCT/AU03/00719

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| | t Document Cited in Search Report | | | Pate | nt Family Member | |
|----|--------------------------------------|----|-----------|------|------------------|--------------|
| EP | 1 300 159 | AU | 67824/01 | wo | 02/002552 | |
| US | 5 942 402 | EP | 0 918 532 | AU | 37439/97 | |
| wо | 98/05349 | US | 5 942 402 | | | |
| wo | 03/014082 | | | | | END OF ANNEX |